Overview

Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria

Status:
Completed

Trial end date:
2021-06-28

Target enrollment:

Participant gender:

Summary

This study aims to determine the most effective and tolerable dose at the shortest dosing regimen of the investigational drug KAF156 in combination with a solid dispersion formulation of lumefantrine (LUM-SDF) in adult/adolescent and pediatric patients with uncomplicated P. falciparum malaria. There is unmet medical need for anti-malarial treatment with new mechanism of action to reduce probability of developing resistance, and for duration shorter than 3 days of treatment and/or reduced pill burden.

Phase:

Phase 2

Details

Lead Sponsor:

Novartis Pharmaceuticals

Collaborator:

Medicines for Malaria Venture

Treatments:

Artemether-lumefantrine combination
Artemether, Lumefantrine Drug Combination